Related Experiment Videos
Treatment of paediatric cerebral palsy with Dysport
1Molecular Medicine Unit, University of Leeds.
Insights
Dysport, a botulinum toxin type A treatment, is now approved for children aged 2+ with cerebral palsy-related dynamic equinus foot deformity. This treatment reduces muscle tone, improving function and easing pain and splint use.
Area of Science:
- Neurology
- Pharmacology
- Pediatrics
Background:
- Cerebral palsy (CP) frequently causes dynamic equinus foot deformity due to spasticity.
- This condition impacts mobility, function, and quality of life in affected children.
- Current management often involves physiotherapy and orthotics, with varying success.
Purpose of the Study:
- To announce the expanded license for Dysport (Clostridium botulinum type A toxin-haemagglutin complex) in pediatric patients.
- To highlight Dysport's role in managing dynamic equinus foot deformity in children with cerebral palsy.
- To outline the benefits of Dysport in this specific pediatric population.
Main Methods:
- The study is based on the extended licensing of Dysport.
- Involves the administration of Clostridium botulinum type A toxin-haemagglutin complex.
- Focuses on pediatric patients aged 2 years and older with cerebral palsy-induced spasticity.
Main Results:
- Dysport is now indicated for children aged 2 years and older with dynamic equinus foot deformity.
- The treatment effectively reduces muscle tone associated with cerebral palsy.
- Improvements in function, pain relief, and ease of splint application and tolerability are observed.
Conclusions:
- Dysport offers a new therapeutic option for managing dynamic equinus foot deformity in young children with cerebral palsy.
- The drug's ability to reduce spasticity leads to significant functional and symptomatic benefits.
- This expanded indication supports improved management and quality of life for pediatric patients.
Abstract:
Dysport (Clostridium botulinum type A toxin-haemagglutin complex) has had its licence extended to include treatment of children aged 2 years and over with dynamic equinus foot deformity, caused by spasticity associated with cerebral palsy. Dysport reduces muscle tone, thus improving function, relieving pain, and facilitating physiotherapy, application and tolerability of splints.